Unclaimed brand
At Eledon our mission is One Transplant for Life. “There has been little innovation in immunomodulatory therapy for organ transplants since the approval of tacrolimus over 30 years ago. Organ transplant recipients deserve better. Targeting the CD40 Ligand pathway may provide significant advantages over current treatment options, including the ability to more effectively control immune […]
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#0B9FD0
Cerulean
11, 159, 208
195, 90, 43
95, 24, 0, 18
#FB6962
Bittersweet
251, 105, 98
3, 95, 68
0, 58, 61, 2
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
Eledon Pharmaceuticals, Inc. With a focus on organ and cellular transplantation, as well as autoimmune and neurodegenerative diseases, Eledon Pharmaceuticals aims to provide potential treatments for these conditions. At the forefront of their research is their lead program, tegoprubart, a humanized IgG1 anti-CD40L antibody with a high affinity for CD40L.
This groundbreaking antibody has the potential to be a best-in-class treatment option for patients in need. The CD40/CD40L pathway is known to play a crucial role in promoting inflammatory responses in conditions such as autoimmune diseases, transplant rejection, and neuroinflammation. Driven by data and science, Eledon Pharmaceuticals has a strategic vision to develop and commercialize next-generation anti-CD40L pathway antibodies, prioritizing patient well-being.
With a deep understanding of the CD40/CD40L pathway and ongoing clinical and preclinical studies, Eledon Pharmaceuticals is at the forefront of precision therapies in the biopharmaceutical industry. For more information about Eledon Pharmaceuticals or to stay updated on their latest developments, you can visit their website or contact them directly
Company type
Public Company
Year founded
2020
Company size
11-50 employees
CD40L-targeted immunotherapy
Transplant rejection therapeutics
Kidney transplant immunosuppression
Islet cell transplantation
ALS immunology research
